David Bruce - IRIDEX CEO President
| IRIX Stock | USD 1.74 0.05 2.79% |
CEO
Mr. David I. Bruce is President, Chief Executive Officer, Director of the Company. He most recently served as COO for Catheter Robotics, a privately held, commercial stage, remote catheter systems company. There he was responsible for planning and executing strategy for commercial market penetration, clinical studies and additional regulatory clearances for label expansion. Prior to that, Bruce served as President and CEO and Director of Arstasis, an arterial access device company, which he transitioned from development to commercialization and growth. Before Arstasis Bruce served as CEO and Director of Patient Safety Technologies, CEO and Director of EP MedSystems, and Platform General Manager of the AcuNav Catheter Business for Siemens Medical Solutions Ultrasound Division. Bruce began his career in engineering roles at Applied Materials and Optical Storage International. He holds a MBA from the Wharton School at the University of Pennsylvania and a BS from the University of California, Berkeley. since 2019.
| Age | 65 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 1212 Terra Bella Avenue, Mountain View, CA, United States, 94043 |
| Phone | 650 940 4700 |
| Web | https://www.iridex.com |
David Bruce Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Bruce against IRIDEX stock is an integral part of due diligence when investing in IRIDEX. David Bruce insider activity provides valuable insight into whether IRIDEX is net buyers or sellers over its current business cycle. Note, IRIDEX insiders must abide by specific rules, including filing SEC forms every time they buy or sell IRIDEX'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Bruce over three months ago Acquisition by David Bruce of 27397 shares of FGI Industries subject to Rule 16b-3 |
IRIDEX Management Efficiency
The company has return on total asset (ROA) of (0.2089) % which means that it has lost $0.2089 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5028) %, meaning that it created substantial loss on money invested by shareholders. IRIDEX's management efficiency ratios could be used to measure how well IRIDEX manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.21 in 2024. Return On Capital Employed is likely to rise to -0.28 in 2024. At this time, IRIDEX's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.5 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 4.4 M in 2024.Similar Executives
| Found 11 records | CEO Age | ||
| Steven Foster | Tenon Medical | 56 | |
| Ronald MD | Rxsight | 61 | |
| Jeffrey Frelick | Bone Biologics Corp | 58 | |
| Nicholas Curtis | LENSAR Inc | 68 | |
| Michael Stewart | STRATA Skin Sciences | 67 | |
| Karen Zaderej | Axogen Inc | 62 | |
| Massimo Calafiore | Orthofix Medical | 52 | |
| Steven Williamson | Pulmonx Corp | 51 | |
| Glendon French | Pulmonx Corp | 62 | |
| Dolev Rafaeli | STRATA Skin Sciences | 60 | |
| Gary Maharaj | SurModics | 61 | |
Management Performance
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.21 |
IRIDEX Leadership Team
Elected by the shareholders, the IRIDEX's board of directors comprises two types of representatives: IRIDEX inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IRIDEX. The board's role is to monitor IRIDEX's management team and ensure that shareholders' interests are well served. IRIDEX's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IRIDEX's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Bruce, CEO President | ||
| Leigh Salvo, Head Relations | ||
| Patrick Mercer, Chief Officer | ||
| Fuad Ahmad, Interim Officer | ||
| Scott JD, Executive Chairman |
IRIDEX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IRIDEX a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.23) % | ||||
| Operating Margin | (0.16) % | ||||
| Current Valuation | 30.83 M | ||||
| Shares Outstanding | 16.64 M | ||||
| Shares Owned By Insiders | 20.67 % | ||||
| Shares Owned By Institutions | 20.05 % | ||||
| Number Of Shares Shorted | 307.13 K | ||||
| Price To Earning | (6.30) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for IRIDEX Stock Analysis
When running IRIDEX's price analysis, check to measure IRIDEX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IRIDEX is operating at the current time. Most of IRIDEX's value examination focuses on studying past and present price action to predict the probability of IRIDEX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IRIDEX's price. Additionally, you may evaluate how the addition of IRIDEX to your portfolios can decrease your overall portfolio volatility.